Bad Krozingen, Germany

Alexander Bilz

This inventor holds 1 USPTO granted patent. Top assignee: Speedel Pharma Ag. Active years: 2008.


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Alexander Bilz: Innovator in Pyridinyl-Sulfonamide Research

Introduction

Alexander Bilz is a notable inventor based in Bad Krozingen, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of pyridinyl-sulfonamide compounds. His work has implications for the treatment of various medical conditions through the modulation of endothelin receptors.

Latest Patents

Bilz holds a patent for "Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists." This patent describes crystalline forms A and B of 5-methyl-pyridine-2-sulfonic acid [6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-amide of formula (I). Notably, form B is identified as the most stable form. Additionally, the compound forms solvates with various solvents, including ethanol, acetone, and dichloromethane, enhancing its versatility in pharmaceutical applications.

Career Highlights

Bilz is currently associated with Speedel Pharma AG, where he continues to advance his research in pharmaceutical sciences. His innovative work has positioned him as a key figure in the development of new therapeutic agents.

Collaborations

He has collaborated with esteemed colleagues such as Thierry Briand and Fritz Blatter, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Alexander Bilz's contributions to the field of medicinal chemistry, particularly through his patent on pyridinyl-sulfonamide compounds, highlight his role as an influential inventor. His ongoing work at Speedel Pharma AG continues to pave the way for advancements in therapeutic solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…